302 related articles for article (PubMed ID: 35506332)
21. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
22. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
23. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
24. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
Huth F; Gardin A; Umehara K; He H
Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
26. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
[TBL] [Abstract][Full Text] [Related]
28. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
29. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
31. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
Barth A; Perry CR; Shabbir S; Zamek-Gliszczynski MJ; Thomas S; Dumont EF; Brimhall DB; Nguyen D; Srinivasan M; Swift B
Clin Transl Sci; 2023 Apr; 16(4):647-661. PubMed ID: 36642822
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
33. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
[TBL] [Abstract][Full Text] [Related]
34. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
35. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
36. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
37. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
38. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
[TBL] [Abstract][Full Text] [Related]
39. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
40. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
